Meds & supplements › hepatitis B immune globulin
Medicine · Human Immunoglobulin
hepatitis B immune globulin
Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- Perinatal Exposure of Infants Born to HBsAg-positive Mothers: Infants born to mothers positive for HBsAg with or without HBeAg 12.
- Sexual Exposure to HBsAg-positive Persons: Sexual partners of HBsAg-positive persons.
- Household Exposure to Persons with Acute HBV Infection: Infants less than 12 months old whose mother or primary caregiver is positive for HBsAg.
- Do not take if
- Individuals known to have anaphylactic or severe systemic reactions to the parenteral administration of human globulin preparations should not receive HepaGam B.
- Individuals who are deficient in IgA may have the potential to develop anti-IgA antibodies and have an anaphylactoid reaction.
- HepaGam B contains less than 40 micrograms per milliliter of IgA.
- For postexposure prophylaxis indications, HepaGam B must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B should be given only if the expected benefits outweigh the potential risks.
What it is used for
HepaGam B [Hepatitis B immune globulin intravenous (Human)] is an intravenous immune globulin indicated for the following:
Side effects, and when to stop
The only adverse reactions observed in clinical trial subjects were hypotension and nausea (2% of clinical trial subjects).
Who should not take it
- Individuals known to have anaphylactic or severe systemic reactions to the parenteral administration of human globulin preparations should not receive HepaGam B.
- Individuals who are deficient in IgA may have the potential to develop anti-IgA antibodies and have an anaphylactoid reaction.
- HepaGam B contains less than 40 micrograms per milliliter of IgA.
- For postexposure prophylaxis indications, HepaGam B must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B should be given only if the expected benefits outweigh the potential risks.
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. hepatitis B immune globulin; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/hepatitis-b-immune-globulin
- APA 7th
sofidex. (2026, August 2). hepatitis B immune globulin. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/hepatitis-b-immune-globulin
- AMA 11th
hepatitis B immune globulin. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/hepatitis-b-immune-globulin
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.